Angiotensin II and oxidative stress in the failing heart

Antioxidants and Redox Signaling

Volumn 19, Issue 10, 2013, Pages 1095-1109

  Zablocki, Daniela ^a   Sadoshima, Junichi ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CANDESARTAN; ENALAPRIL; NITRIC OXIDE SYNTHASE; RAMIPRIL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TELMISARTAN; VALSARTAN; XANTHINE OXIDASE;

ACUTE HEART INFARCTION; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; FEEDBACK SYSTEM; HEART FAILURE; HEART FUNCTION; HUMAN; HYPERTENSION; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II; ANIMALS; CARDIOVASCULAR DISEASES; HEART FAILURE; HUMANS; MITOCHONDRIA; NADPH OXIDASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM;

EID: 84884176816     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4588     Document Type: Review

References (154)

1. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316: 1429-1435, 1987.
2. Ago T, Kuroda J, Pain J, Fu C, Li H, and Sadoshima J. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res 106: 1253-1264, 2010.
3. Ago T, Liu T, Zhai P, Chen W, Li H, Molkentin JD, Vatner SF, and Sadoshima J. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 133: 978-993, 2008.
4. Backs J, Song K, Bezprozvannaya S, Chang S, and Olson EN. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest 116: 1853-1864, 2006.
5. Basso N, Cini R, Pietrelli A, Ferder L, Terragno NA, and Inserra F. Protective effect of long-term angiotensin II inhibition. Am J Physiol Heart Circ Physiol 293: H1351-H1358, 2007.
6. Baumer AT, Flesch M, Wang X, Shen Q, Feuerstein GZ, and Bohm M. Antioxidative enzymes in human hearts with idiopathic dilated cardiomyopathy. J Mol Cell Cardiol 32: 121-130, 2000.
7. Bedard K and Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313, 2007.
8. Bendall JK, Cave AC, Heymes C, Gall N, and Shah AM. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105: 293-296, 2002.
9. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P,Morigi M, Coffman TM, and Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 119: 524-530, 2009.
10. Bodiga S, Zhong JC, Wang W, Basu R, Lo J, Liu GC, Guo D, Holland SM, Scholey JW, Penninger JM, Kassiri Z, and Oudit GY. Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47phox NADPH oxidase subunit. Cardiovasc Res 91: 151-161, 2011.
11. Borchi E, Bargelli V, Stillitano F, Giordano C, Sebastiani M, Nassi PA, d'Amati G, Cerbai E, and Nediani C. Enhanced ROS production by NADPH oxidase is correlated to changes in antioxidant enzyme activity in human heart failure. Biochim Biophys Acta 1802: 331-338, 2010.
12. Burniston JG, Saini A, Tan LB, and Goldspink DF. Angiotensin II induces apoptosis in vivo in skeletal, as well as cardiac, muscle of the rat. Exp Physiol 90: 755-761, 2005.
13. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, Cave AC, and Shah AM. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 93: 802-805, 2003.
14. Cameron VA, Mocatta TJ, Pilbrow AP, Frampton CM, Troughton RW, Richards AM, and Winterbourn CC. Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. Hypertension 47: 1155-1161, 2006.
15. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, Marban E, and Hare JM. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104: 2407-2411, 2001.
16. Dai DF and Rabinovitch P. Mitochondrial oxidative stress mediates induction of autophagy and hypertrophy in angiotensin- II treated mouse hearts. Autophagy 7: 917-918, 2011.
17. Dai DF, Johnson SC, Villarin JJ, Chin MT, Nieves-Cintron M, Chen T, Marcinek DJ, Dorn GW, 2nd, Kang YJ, Prolla TA, Santana LF, and Rabinovitch PS. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res 108: 837-846, 2011.
18. Dell'Italia LJ and Husain A. Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr Opin Cardiol 17: 374-379, 2002.
19. Der Sarkissian S, Grobe JL, Yuan L, Narielwala DR, Walter GA, Katovich MJ, and Raizada MK. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 51: 712-718, 2008.
20. Dieterich S, Bieligk U, Beulich K, Hasenfuss G, and Prestle J. Gene expression of antioxidative enzymes in the human heart: increased expression of catalase in the end-stage failing heart. Circulation 101: 33-39, 2000.
21. Ebrahimian T, He Y, Schiffrin EL, and Touyz RM. Differential regulation of thioredoxin and NAD(P)H oxidase by angiotensin II in male and female mice. J Hypertens 25: 1263-1271, 2007.
22. Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV, Bartlett RK, Lowe JS, O'Donnell SE, Aykin-Burns N, Zimmerman MC, Zimmerman K, Ham AJ, Weiss RM, Spitz DR, Shea MA, Colbran RJ, Mohler PJ, and Anderson ME. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 133: 462-474, 2008.
23. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, Dechend R, Fiebeler A, Burckle C, Contrepas A, Jan Danser AH, Bader M, Nguyen G, Luft FC, and Muller DN. Prorenin and renin-induced extracellular signalregulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 51: 682-688, 2008.
24. Ferrario CM. New physiological concepts of the reninangiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension 55: 445-452, 2010.
25. Ferreira AJ, Santos RA, Bradford CN, Mecca AP, Sumners C, Katovich MJ, and Raizada MK. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 55: 207-213, 2010.
26. Figtree GA, Liu CC, Bibert S, Hamilton EJ, Garcia A, White CN, Chia KK, Cornelius F, Geering K, and Rasmussen HH. Reversible oxidative modification: a key mechanism of Na+ -K + pump regulation. Circ Res 105: 185-193, 2009.
27. Guo P, Nishiyama A, Rahman M, Nagai Y, Noma T, Namba T, Ishizawa M, Murakami K, Miyatake A, Kimura S, Mizushige K, Abe Y, Ohmori K, and Kohno M. Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade. J Hypertens 24: 1097-1104, 2006.
28. Gurusamy N and Das DK. Autophagy, redox signaling, and ventricular remodeling. Antioxid Redox Signal 11: 1975- 1988, 2009.
29. Hariharan N, Zhai P, and Sadoshima J. Oxidative stress stimulates autophagic flux during ischemia/reperfusion. Antioxid Redox Signal 14: 2179-2190, 2011.
30. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, and Shah AM. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41: 2164-2171, 2003.
31. Howe CJ, Lahair MM, McCubrey JA, and Franklin RA. Redox regulation of the calcium/calmodulin-dependent protein kinases. J Biol Chem 279: 44573-44581, 2004.
32. Huisamen B, Perel SJ, Friedrich SO, Salie R, Strijdom H, and Lochner A. ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance. Mol Cell Biochem 349: 21-31, 2011.
33. Ichihara S, Senbonmatsu T, Price E, Jr., Ichiki T, Gaffney FA, and Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 104: 346-351, 2001.
34. Israili ZH, VelascoM, and Bermudez V. Direct renin inhibitors as antihypertensive agents. Am J Ther 17: 237-254, 2010.
35. Ito N, Ohishi M, Yamamoto K, Tatara Y, Shiota A, Hayashi N, Komai N, Yanagitani Y, Rakugi H, and Ogihara T. Renin-angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats. Am J Hypertens 20: 792-799, 2007.
36. Iusuf D, Henning RH, van Gilst WH, and Roks AJ. Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol 585: 303-312, 2008.
37. Jekell A, Hossain A, Alehagen U, Dahlstrom U, and Rosen A. Elevated circulating levels of thioredoxin and stress in chronic heart failure. Eur J Heart Fail 6: 883-890, 2004.
38. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, and Yancy CW. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119: 1977- 2016, 2009.
39. Jia N, Dong P, Ye Y, Qian C, and Dai Q. Allopurinol Attenuates Oxidative Stress and Cardiac Fibrosis in Angiotensin II-Induced Cardiac Diastolic Dysfunction. Cardiovasc Ther 30: 117-123, 2012.
40. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, and Shah AM. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 20: 1546-1548, 2006.
41. Kajstura J, Bolli R, Sonnenblick EH, Anversa P, and Leri A. Cause of death: suicide. J Mol Cell Cardiol 40: 425-437, 2006.
42. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, and Anversa P. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 29: 859-870, 1997.
43. Kakishita M, Nakamura K, Asanuma M, Morita H, Saito H, Kusano K, Nakamura Y, Emori T, Matsubara H, Sugaya T, Ogawa N, and Ohe T. Direct evidence for increased hydroxyl radicals in angiotensin II-induced cardiac hypertrophy through angiotensin II type 1a receptor. J Cardiovasc Pharmacol 42 Suppl 1: S67-S70, 2003.
44. Kase H, Hashikabe Y, Uchida K, Nakanishi N, and Hattori Y. Supplementation with tetrahydrobiopterin prevents the cardiovascular effects of angiotensin II-induced oxidative and nitrosative stress. J Hypertens 23: 1375-1382, 2005.
45. Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu PP, Scholey JW, Penninger JM, and Oudit GY. Loss of angiotensinconverting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail 2: 446-455, 2009.
46. Kataja-Tuomola MK, Kontto JP, Mannisto S, Albanes D, and Virtamo JR. Effect of alpha-tocopherol and betacarotene supplementation on macrovascular complications and total mortality from diabetes: results of the ATBC Study. Ann Med 42: 178-186, 2010.
47. Katragadda S and Arora RR. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects. Am J Ther 17: e11-e23, 2010.
48. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J, Hongo M, Noda T, Nakayama J, Sagara J, Taniguchi S, and Ikeda U. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 123: 594-604, 2011.
49. Khaper N and Singal PK. Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats. J Am Coll Cardiol 37: 1461-1466, 2001.
50. Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N, Chiang YT, and Cohn JN. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 6: 937-945, 2004.
51. Kumar R, Singh VP, and Baker KM. The intracellular reninangiotensin system in the heart. Curr Hypertens Rep 11: 104-110, 2009.
52. Kurdi M, De Mello WC, and Booz GW. Working outside the system: an update on the unconventional behavior of the renin-angiotensin system components. Int J Biochem Cell Biol 37: 1357-1367, 2005.
53. Kuroda J and Sadoshima J. NADPH oxidase and cardiac failure. J Cardiovasc Transl Res 3: 314-320, 2010.
54. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, and Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci U S A 107: 15565-15570, 2010.
55. Landmesser U, Spiekermann S, Preuss C, Sorrentino S, Fischer D, Manes C, Mueller M, and Drexler H. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol 27: 943-948, 2007.
56. Li JM, Gall NP, Grieve DJ, Chen M, and Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40: 477-484, 2002.
57. Li JM and Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol 287: R1014-R1030, 2004.
58. Li SY, Yang X, Ceylan-Isik AF, Du M, Sreejayan N, and Ren J. Cardiac contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco(endo)plasmic reticulum Ca2 + -ATPase and myosin heavy chain isozyme switch. Diabetologia 49: 1434-1446, 2006.
59. Lijnen PJ, van Pelt JF, and Fagard RH. Downregulation of manganese superoxide dismutase by angiotensin II in cardiac fibroblasts of rats: Association with oxidative stress in myocardium. Am J Hypertens 23: 1128-1135, 2010.
60. Liu Q, Wang G, Zhou G, Tan Y, Wang X, Wei W, Liu L, Xue W, Feng W, and Cai L. Angiotensin II-induced p53- dependent cardiac apoptotic cell death: its prevention by metallothionein. Toxicol Lett 191: 314-320, 2009.
61. Liu Y and Min W. Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res 90: 1259-1266, 2002.
62. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JF, and Gerstein HC. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25: 1919- 1927, 2002.
63. Looi YH, Grieve DJ, Siva A, Walker SJ, Anilkumar N, Cave AC, Marber M, Monaghan MJ, and Shah AM. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 51: 319-325, 2008.
64. Lopez Farre A and Casado S. Heart failure, redox alterations, and endothelial dysfunction. Hypertension 38: 1400-1405, 2001.
65. Lu L, Quinn MT, and Sun Y. Oxidative stress in the infarcted heart: role of de novo angiotensin II production. Biochem Biophys Res Commun 325: 943-951, 2004.
66. Maack C, Kartes T, Kilter H, Schafers HJ, Nickenig G, Bohm M, and Laufs U. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 108: 1567-1574, 2003.
67. Maejima Y, Kuroda J, Matsushima S, Ago T, and Sadoshima J. Regulation of myocardial growth and death by NADPH oxidase. J Mol Cell Cardiol 50: 408-416, 2011.
68. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, and Yusuf S. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372: 547-553, 2008.
69. Matsuhisa S, Otani H, Okazaki T, Yamashita K, Akita Y, Sato D, Moriguchi A, Imamura H, and Iwasaka T. Angiotensin II type 1 receptor blocker preserves tolerance to ischemia- reperfusion injury in Dahl salt-sensitive rat heart. Am J Physiol Heart Circ Physiol 294: H2473-H2479, 2008.
70. Matsuhisa S, Otani H, Okazaki T, Yamashita K, Akita Y, Sato D, Moriguchi A, and Iwasaka T. N-acetylcysteine abolishes the protective effect of losartan against left ventricular remodeling in cardiomyopathy hamster. Antioxid Redox Signal 10: 1999-2008, 2008.
71. Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T, Levine B, and Sadoshima J. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMPactivated protein kinase and Beclin 1 in mediating autophagy. Circ Res 100: 914-922, 2007.
72. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, and Pfeffer MA. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARMAdded trial. Lancet 362: 767-771, 2003.
73. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, and Lewsey J. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 1: 17-24, 2008.
74. Mellin V, Isabelle M, Oudot A, Vergely-Vandriesse C, Monteil C, Di Meglio B, Henry JP, Dautreaux B, Rochette L, Thuillez C, and Mulder P. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J 26: 1544-1550, 2005.
75. Mercure C, Yogi A, Callera GE, Aranha AB, BaderM, Ferreira AJ, Santos RA, Walther T, Touyz RM, and Reudelhuber TL. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 103: 1319-1326, 2008.
76. Mervaala E, Biala A, Merasto S, Lempiainen J, Mattila I, Martonen E, Eriksson O, Louhelainen M, Finckenberg P, Kaheinen P, Muller DN, Luft FC, Lapatto R, and Oresic M. Metabolomics in angiotensin II-induced cardiac hypertrophy. Hypertension 55: 508-515, 2010.
77. Miguel-Carrasco JL, Zambrano S, Blanca AJ, Mate A, and Vazquez CM. Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. J Inflamm (Lond) 7: 21, 2010.
78. Minhas KM, Saraiva RM, Schuleri KH, Lehrke S, Zheng M, Saliaris AP, Berry CE, Barouch LA, Vandegaer KM, Li D, and Hare JM. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res 98: 271-279, 2006.
79. Miyazaki M, Takai S, Jin D, and Muramatsu M. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther 112: 668-676, 2006.
80. Moe G, Konig A, Liu P, and Jugdutt BI. Selective type 1 angiotensin II receptor blockade attenuates oxidative stress and regulates angiotensin II receptors in the canine failing heart. Mol Cell Biochem 317: 97-104, 2008.
81. Moens AL and Kass DA. Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease. J Cardiovasc Pharmacol 50: 238-246, 2007.
82. Mollnau H, Oelze M, August M, Wendt M, Daiber A, Schulz E, Baldus S, Kleschyov AL, Materne A, Wenzel P, Hink U, Nickenig G, Fleming I, and Munzel T. Mechanisms of increased vascular superoxide production in an experimental model of idiopathic dilated cardiomyopathy. Arterioscler Thromb Vasc Biol 25: 2554-2559, 2005.
83. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Forstermann U, Meinertz T, Griendling K, and Munzel T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90: E58-E65, 2002.
84. Moltzer E, Verkuil AV, van Veghel R, Danser AH, and van Esch JH. Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation. Hypertension 55: 516-522, 2010.
85. Murtaza I, Wang HX, Feng X, Alenina N, Bader M, Prabhakar BS, and Li PF. Down-regulation of catalase and oxidative modification of protein kinase CK2 lead to the failure of apoptosis repressor with caspase recruitment domain to inhibit cardiomyocyte hypertrophy. J Biol Chem 283: 5996-6004, 2008.
86. Nakagami H, Takemoto M, and Liao JK. NADPH oxidasederived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 35: 851-859, 2003.
87. Nediani C, Borchi E, Giordano C, Baruzzo S, Ponziani V, Sebastiani M, Nassi P, Mugelli A, d'Amati G, and Cerbai E. NADPH oxidase-dependent redox signaling in human heart failure: relationship between the left and right ventricle. J Mol Cell Cardiol 42: 826-834, 2007.
88. Nishida M, Tanabe S, Maruyama Y, Mangmool S, Urayama K, Nagamatsu Y, Takagahara S, Turner JH, Kozasa T, Kobayashi H, Sato Y, Kawanishi T, Inoue R, Nagao T, and Kurose H. G alpha 12/13- and reactive oxygen speciesdependent activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase by angiotensin receptor stimulation in rat neonatal cardiomyocytes. J Biol Chem 280: 18434-18441, 2005.
89. Nishio M, Sakata Y, Mano T, Yoshida J, Ohtani T, Takeda Y, Miwa T, Masuyama T, Yamamoto K, and Hori M. Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure. J Hypertens 25: 455-461, 2007.
90. Ocaranza MP, Lavandero S, Jalil JE, Moya J, Pinto M, Novoa U, Apablaza F, Gonzalez L, Hernandez C, Varas M, Lopez R, Godoy I, Verdejo H, and Chiong M. Angiotensin- (1-9) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens 28: 1054-1064, 2010.
91. Ohtahara A, Hisatome I, Yamamoto Y, Furuse M, Sonoyama K, Furuse Y, Hamada T, Katoh M, Watanabe M, Kinugawa T, Ogino K, Igawa O, Shimomura T, Murakami F, Yamamoto T, and Shigemasa C. The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and alpha1-blockers. J Hypertens 19: 575-582, 2001.
92. Oka S, Ago T, Kitazono T, Zablocki D, and Sadoshima J. The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy. J Mol Med (Berl) 87: 785-791, 2009.
93. Oudit GY, Kassiri Z, Patel MP, Chappell M, Butany J, Backx PH, Tsushima RG, Scholey JW, Khokha R, and Penninger JM. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res 75: 29-39, 2007.
94. Palomeque J, Rueda OV, Sapia L, Valverde CA, Salas M, Petroff MV, and Mattiazzi A. Angiotensin II-induced oxidative stress resets the Ca2 + dependence of Ca2 +- calmodulin protein kinase II and promotes a death pathway conserved across different species. Circ Res 105: 1204-1212, 2009.
95. Peng H, Carretero OA, Liao TD, Peterson EL, and Rhaleb NE. Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensinconverting enzyme inhibitor captopril in hypertension. Hypertension 49: 695-703, 2007.
96. Pierzchalski P, Reiss K, Cheng W, Cirielli C, Kajstura J, Nitahara JA, Rizk M, Capogrossi MC, and Anversa P. p53 Induces myocyte apoptosis via the activation of the reninangiotensin system. Exp Cell Res 234: 57-65, 1997.
97. Porrello ER, D'Amore A, Curl CL, Allen AM, Harrap SB, Thomas WG, and Delbridge LM. Angiotensin II type 2 receptor antagonizes angiotensin II type 1 receptor-mediated cardiomyocyte autophagy. Hypertension 53: 1032-1040, 2009.
98. Porrello ER and Delbridge LM. Cardiomyocyte autophagy is regulated by angiotensin II type 1 and type 2 receptors. Autophagy 5: 1215-1216, 2009.
99. Privratsky JR, Wold LE, Sowers JR, Quinn MT, and Ren J. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension 42: 206-212, 2003.
100. Prosser HC, Forster ME, Richards AM, and Pemberton CJ. Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. Cardiovasc Res 82: 40-50, 2009.
101. Qin F, Patel R, Yan C, and Liu W. NADPH oxidase is involved in angiotensin II-induced apoptosis in H9C2 cardiac muscle cells: effects of apocynin. Free Radic Biol Med 40: 236-246, 2006.
102. Rasmussen HH, Hamilton EJ, Liu CC, and Figtree GA. Reversible oxidative modification: implications for cardiovascular physiology and pathophysiology. Trends Cardiovasc Med 20: 85-90, 2010.
103. Re RN and Cook JL. The mitochondrial component of intracrine action. Am J Physiol Heart Circ Physiol 299: H577-H583, 2010.
104. Sam F, Kerstetter DL, Pimental DR, Mulukutla S, Tabaee A, Bristow MR, Colucci WS, and Sawyer DB. Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J Card Fail 11: 473-480, 2005.
105. Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, and Liao JK. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A 103: 7432-7437, 2006.
106. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, and Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 26: 1749-1760, 2007.
107. Schluter KD and Wenzel S. Angiotensin II: a hormone involved in and contributing to pro-hypertrophic cardiac networks and target of anti-hypertrophic cross-talks. Pharmacol Ther 119: 311-325, 2008.
108. Senbonmatsu T, Ichihara S, Price E, Jr., Gaffney FA, and Inagami T. Evidence for angiotensin II type 2 receptormediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest 106: R25-R29, 2000.
109. Shang LL, Sanyal S, Pfahnl AE, Jiao Z, Allen J, Liu H, and Dudley SC, Jr. NF-kappaB-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II. Am J Physiol Cell Physiol 294: C372-C379, 2008.
110. Shimoni Y, Chen K, Emmett T, and Kargacin G. Aldosterone and the autocrine modulation of potassium currents and oxidative stress in the diabetic rat heart. Br J Pharmacol 154: 675-687, 2008.
111. Shimoni Y, Hunt D, Chen K, Emmett T, and Kargacin G. Differential autocrine modulation of atrial and ventricular potassium currents and of oxidative stress in diabetic rats. Am J Physiol Heart Circ Physiol 290: H1879-H1888, 2006.
112. Shimoni Y, Hunt D, Chuang M, Chen KY, Kargacin G, and Severson DL. Modulation of potassium currents by angiotensin and oxidative stress in cardiac cells from the diabetic rat. J Physiol 567: 177-190, 2005.
113. Singh VP, Le B, Khode R, Baker KM, and Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes 57: 3297-3306, 2008.
114. Siragy HM. Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Adv Ther 27: 257-284, 2010.
115. Smith RS, Jr., Agata J, Xia CF, Chao L, and Chao J. Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci 76: 2457-2471, 2005.
116. Sorescu D and Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail 8: 132-140, 2002.
117. Steckelings UM, Kaschina E, and Unger T. The AT2 receptor- a matter of love and hate. Peptides 26: 1401-1409, 2005.
118. Suematsu N, Tsutsui H, Wen J, Kang D, Ikeuchi M, Ide T, Hayashidani S, Shiomi T, Kubota T, Hamasaki N, and Takeshita A. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 107: 1418-1423, 2003.
119. Sukumaran V, Watanabe K, Veeraveedu PT, Gurusamy N, Ma M, Thandavarayan RA, Lakshmanan AP, Yamaguchi K, Suzuki K, and Kodama M. Olmesartan, an AT1 antagonist, attenuates oxidative stress, endoplasmic reticulum stress and cardiac inflammatory mediators in rats with heart failure induced by experimental autoimmune myocarditis. Int J Biol Sci 7: 154-167, 2011.
120. Sun Y. Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc Res 81: 482-490, 2009.
121. Takai S, Jin D, and Miyazaki M. New approaches to blockade of the renin-angiotensin-aldosterone system: chymase as an important target to prevent organ damage. J Pharmacol Sci 113: 301-309, 2010.
122. Takenaka H, Kihara Y, Iwanaga Y, Onozawa Y, Toyokuni S, and Kita T. Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension. J Mol Cell Cardiol 41: 989-997, 2006.
123. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, Lazzarino G, Paolocci N, Gabrielson KL,Wang Y, and Kass DA. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 115: 1221-1231, 2005.
124. Tamura K, Tanaka Y, Tsurumi Y, Azuma K, Shigenaga A, Wakui H, Masuda S, andMatsuda M. The role of angiotensin AT1 receptor-associated protein in renin-angiotensin system regulation and function. Curr Hypertens Rep 9: 121-127, 2007.
125. Tanaka M, Umemoto S, Kawahara S, Kubo M, Itoh S, Umeji K, and Matsuzaki M. Angiotensin II type 1 receptor antagonist and angiotensin-converting enzyme inhibitor altered the activation of Cu/Zn-containing superoxide dismutase in the heart of stroke-prone spontaneously hypertensive rats. Hypertens Res 28: 67-77, 2005.
126. Tanno M, Kuno A, Yano T, Miura T, Hisahara S, Ishikawa S, Shimamoto K, and Horio Y. Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem 285: 8375-8382, 2010.
127. Theres H, Wagner KD, Schulz S, Strube S, Leiterer KP, Romberg D, Gunther J, Scholz H, Baumann G, and Schimke I. Oxygen radical system in chronic infarcted rat heart: the effect of combined beta blockade and ACE inhibition. J Cardiovasc Pharmacol 35: 708-715, 2000.
128. Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, Erbs S, Linke A, Diederich KW, Nowak M, Desch S, Gutberlet M, and Schuler G. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo- Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction NACC) Trial. J Am Coll Cardiol 55: 2201-2209, 2010.
129. Trask AJ, Groban L, Westwood BM, Varagic J, Ganten D, Gallagher PE, Chappell MC, and Ferrario CM. Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats. Am J Hypertens 23: 687-693, 2010.
130. Trask AJ, Jessup JA, Chappell MC, and Ferrario CM. Angiotensin-( 1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol Heart Circ Physiol 294: H2242-H2247, 2008.
131. Tsutamoto T, Wada A, Matsumoto T, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Yamamoto T, Horie H, Sugimoto Y, and Kinoshita M. Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol 37: 2086-2092, 2001.
132. Tsutsui H, Ide T, Hayashidani S, Kinugawa S, Suematsu N, Utsumi H, and Takeshita A. Effects of ACE inhibition on left ventricular failure and oxidative stress in Dahl saltsensitive rats. J Cardiovasc Pharmacol 37: 725-733, 2001.
133. Wakui H, Tamura K, Tanaka Y, Matsuda M, Bai Y, Dejima T, Masuda S, Shigenaga A, Maeda A, Mogi M, Ichihara N, Kobayashi Y, Hirawa N, Ishigami T, Toya Y, Yabana M, Horiuchi M, Minamisawa S, and Umemura S. Cardiacspecific activation of angiotensin II type 1 receptor-associated protein completely suppresses cardiac hypertrophy in chronic angiotensin II-infused mice. Hypertension 55: 1157- 1164, 2010.
134. Wang M, Zhang J, Walker SJ, Dworakowski R, Lakatta EG, and Shah AM. Involvement of NADPH oxidase in ageassociated cardiac remodeling. J Mol Cell Cardiol 48: 765- 772, 2010.
135. Wang Y, Qian C, Roks AJ, Westermann D, Schumacher SM, Escher F, Schoemaker RG, Reudelhuber TL, van Gilst WH, Schultheiss HP, Tschope C, and Walther T. Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarction. Circ Heart Fail 3: 286-293, 2010.
136. Wei CC, Hase N, Inoue Y, Bradley EW, Yahiro E, Li M, Naqvi N, Powell PC, Shi K, Takahashi Y, Saku K, Urata H, Dell'italia LJ, and Husain A. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest 120: 1229-1239, 2010.
137. Wei L, Fahey T, Struthers AD, and MacDonald TM. Association between allopurinol and mortality in heart failure patients: a long-term follow-up study. Int J Clin Pract 63: 1327-1333, 2009.
138. Whaley-Connell A, Govindarajan G, Habibi J, Hayden MR, Cooper SA, Wei Y, Ma L, Qazi M, Link D, Karuparthi PR, Stump C, Ferrario C, and Sowers JR.
139. White CN, Figtree GA, Liu CC, Garcia A, Hamilton EJ, Chia KK, and Rasmussen HH. Angiotensin II inhibits the Na+ -K + pump via PKC-dependent activation of NADPH oxidase. Am J Physiol Cell Physiol 296: C693-C700, 2009.
140. Widder JD, Fraccarollo D, Galuppo P, Hansen JM, Jones DP, Ertl G, and Bauersachs J. Attenuation of angiotensin IIinduced vascular dysfunction and hypertension by overexpression of Thioredoxin 2. Hypertension 54: 338-344, 2009.
141. Wu R, Laplante MA, and de Champlain J. Cyclooxygenase- 2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats. Hypertension 45: 1139-1144, 2005.
142. Xu J, Carretero OA, Liao TD, Peng H, Shesely EG, Liu TS, Yang JJ, Reudelhuber TL, and Yang XP. Local angiotensin II aggravates cardiac remodeling in hypertension. Am J Physiol Heart Circ Physiol 299: H1328-H1338, 2010.
143. Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, Dong YF, Matsuba S, Ogawa H, and Kim-Mitsuyama S. Role of xanthine oxidoreductase in the reversal of diastolic heart failure by candesartan in the salt-sensitive hypertensive rat. Hypertension 50: 657-662, 2007.
144. Yang Y, Ago T, Zhai P, Abdellatif M, and Sadoshima J. Thioredoxin 1 negatively regulates angiotensin II-induced cardiac hypertrophy through upregulation of miR-98/let-7. Circ Res 108: 305-313, 2011.
145. Yayama K and Okamoto H. Angiotensin II-induced vasodilation via type 2 receptor: role of bradykinin and nitric oxide. Int Immunopharmacol 8: 312-318, 2008.
146. Zablocki D and Sadoshima J. Knocking out angiotensin II in the heart. Curr Hypertens Rep 13: 129-135, 2011.
147. Zhang M, Brewer AC, Schroder K, Santos CX, Grieve DJ, Wang M, Anilkumar N, Yu B, Dong X, Walker SJ, Brandes RP, and Shah AM. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci U S A 107: 18121-18126, 2010.
148. Zhang R, Al-Lamki R, Bai L, Streb JW, Miano JM, Bradley J, and Min W. Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner. Circ Res 94: 1483-1491, 2004.
149. Zhao W, Zhao T, Chen Y, Ahokas RA, and Sun Y. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Mol Cell Biochem 317: 43-50, 2008.
150. Zhao Y, McLaughlin D, Robinson E, Harvey AP, Hookham MB, Shah AM, McDermott BJ, and Grieve DJ. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy. Cancer Res 70: 9287-9297, 2010.
151. Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, Loibner H, Wang XH, Penninger JM, Kassiri Z, and Oudit GY. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122: 717-728, 18 p following 728, 2010.
152. Zhou A, Carrell RW, Murphy MP, Wei Z, Yan Y, Stanley PL, Stein PE, Broughton Pipkin F, and Read RJ. A redox switch in angiotensinogen modulates angiotensin release. Nature 468: 108-111, 2010.
153. Zhou G, Li X, Hein DW, Xiang X, Marshall JP, Prabhu SD, and Cai L. Metallothionein suppresses angiotensin IIinduced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J Am Coll Cardiol 52: 655-666, 2008.
154. Zorov DB, Filburn CR, Klotz LO, Zweier JL, and Sollott SJ. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med 192: 1001-1014, 2000.